Samsung Biologics Publishes Prospectus for PolyPeptide Public Tender Offer
PolyPeptide’s board unanimously recommends the cash offer, which values the Swiss drugmaker at about CHF 1.46 billion, Samsung Biologics said.
- On Monday, August 31, 2026, Samsung Biologics published the formal tender offer prospectus for PolyPeptide Group AG, launching a $1.80 billion acquisition of the Swiss contract drugmaker.
- This formal offer follows a pre-announcement on July 20, 2026, as Samsung Biologics seeks to delist PolyPeptide from the SIX Swiss Exchange following settlement.
- Samsung Peptide AG is offering CHF 44.31 per share, representing a 40% premium over the April 10, 2026 unaffected price and CHF 1.46 billion in aggregate equity value.
- PolyPeptide's Board of Directors unanimously recommends shareholders accept the bid, while largest shareholder Draupnir Holding B.V. has committed to tender all of its shares into the offer.
- The main offer period runs from September 15 to October 12, 2026, with Samsung Peptide intending to pursue a squeeze-out of remaining minority shareholders following settlement.
16 Articles
16 Articles
Samsung Biologics to launch takeover bid for PolyPeptide in September - Regional Media News
Aug 31 (Reuters) - Samsung Biologics will launch its takeover offer for Swiss contract drugmaker PolyPeptide Group in September, the South Korean company said in an offer prospectus on Monday. The companies had announced in July that Samsung Biologics would launch an offer of 1.46 [...]
Samsung Biologics to launch takeover bid for PolyPeptide in September
Aug 31 (Reuters) - Samsung Biologics will launch its takeover offer for Swiss contract drugmaker PolyPeptide Group in September, the South Korean company said in an offer prospectus on Monday. The companies had announced in July that Samsung Biol...
연합뉴스-Yonhap News Agency
asiae.co.kr(Seoul = Yonhap News) Reporter Shin Seon-mi = Samsung Biologics [207940] [is pursuing] the acquisition of Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO)...
The Courier-Tribune
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offerPublication of offer prospectus follows pre-announcement on July 20, 2026Largest individual shareholder committed to tender all of its PolyPeptide shares into offerMain offer period expected to last…
Samsung Biologics presents the definitive offer prospectus of its takeover offer for polypeptides. The South Korean contractor offers unchanged CHF 44.31 per polypeptide share.
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
